Oncotarget

Research Papers:

Prognostic effect of liver metastasis in lung cancer patients with distant metastasis

Yijiu Ren, Chenyang Dai, Hui Zheng, Fangyu Zhou, Yunlang She, Gening Jiang, Ke Fei, Ping Yang, Dong Xie and Chang Chen _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:53245-53253. https://doi.org/10.18632/oncotarget.10644

Metrics: PDF 1827 views  |   HTML 2456 views  |   ?  


Abstract

Yijiu Ren1,*, Chenyang Dai1,*, Hui Zheng1, Fangyu Zhou1, Yunlang She1, Gening Jiang1, Ke Fei1, Ping Yang2, Dong Xie1, Chang Chen1

1Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China

2Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA

*These authors contributed equally to this work

Correspondence to:

Chang Chen, email: changchenc@hotmail.com

Dong Xie, email: kongduxd@163.com

Keywords: lung cancer, distant metastasis, prognosis, surveillance epidemiology and end-results database

Received: March 14, 2016     Accepted: July 09, 2016     Published: July 18, 2016

ABSTRACT

Because the need of clinical prognostic evaluation by specific metastatic organ, we aim to analyze the prognostic factors in lung cancer patients with M1b disease with Surveillance Epidemiology and End-Results database (SEER). This retrospective study evaluated lung cancer patients of adenocarcinoma (AD), squamous cell carcinoma (SQCC), and small cell lung cancer (SCLC) selected from SEER. We provided the prognostic correlates of overall survival (OS) and lung cancer-specific survival (LCSS) in this population. 23,679 eligible patients were included. Bone was the most common metastatic site in AD (63.1%) and SQCC (61.1%), while liver was the most prevalent site (61.9%) in SCLC. Single site metastasis was significantly associated with better outcome compared to multiple sites metastases in all patients. Among patients with single site metastasis, OS and LCSS were longer for AD and SCLC if involving brain or bone, with median survival time of 5 to 7 months, comparing to 3 months if invloving liver (all p-values < 0.001). Similarly, among patients with multiple metastases, better outcomes were observed in AD patients (4 vs 3 months; OS and LCSS, p < 0.001) and SCLC patients (6 vs 4 months; OS, p = 0.017; LCSS, p = 0.023) without liver metastasis compared to those with liver metastasis. In conclusion, we estimated multiple survival outcomes by histology of primary tumor and sites of metastasis. Liver metastasis is found to be the worst prognostic factor for AD and SCLC patients with distant metastasis. More in-depth research is warranted to identify patients who are prone to develop distance metastasis, especially to liver.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10644